Nico Gagelmann: Tandem transplant for myeloma patients with sub-optimal responses to induction therapy
Nico Gagelmann, Co-founder and Co-chair the European Society for Blood and Marrow Transplantation (EBMT) Trainee Committee, shared on X:
“Finally out.
Tandem transplant should be reserved to myeloma patients with sub-optimal responses to induction therapy AND a first transplant
Congrats Max Merz and team, BMT Journal.”
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Authors: Nora Grieb, Alexander Oeser, Maximilian Ferle, Franziska Hanke, Sarah Flossdorf, Sandra Sauer, Hartmut Goldschmidt, Carsten Müller-Tidow, Hans-Jürgen Salwender, Roland Fenk, Monika Engelhardt, Robert Zeiser, Vladan Vucinic, Georg-Nikolaus Franke, Igor Wolfgang Blau, Daniel Teschner, Hermann Einsele, Christoph Kimmich, Miriam Kull, Britta Besemer, Nico Gagelmann, Nicolaus Kröger, Thomas Neumuth, Uwe Platzbecker and Maximilian Merz on behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
Nico Gagelmann is a physician and scientist who co-founded and co-chairs the European Society for Blood and Marrow Transplantation (EBMT) Trainee Committee, and he also serves as the chair of the EBMT subcommittee focused on CAR-T cell therapies for plasma cell disorders. His work is particularly impactful in the realm of CAR-T treatments for multiple myeloma, where he has contributed to advancing research and clinical approaches.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023